Merck KGaA Pays C4 Therapeutics US$16 M Upfront for Protein Degraders

By Lucy Haggerty

Pharma Deals Review: Vol 2024 Issue 3 (Table of Contents)

Published: 8 Mar-2024

DOI: 10.3833/pdr.v2024.i3.2857     ISSN: 1756-7874

Section: Research & Development



In yet another move in the protein degradation space, Merck KGaA has signed a strategic discovery research collaboration with C4 Therapeutics focused on two targeted protein degraders against critical oncogenic proteins...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details